Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation.
DIC
platelet activation
poor outcome
sCLEC-2
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Jun 2021
28 Jun 2021
Historique:
received:
19
05
2021
revised:
23
06
2021
accepted:
24
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Disseminated intravascular coagulation (DIC) is induced by excess activation coagulation, and activated platelets are also involved in pathogenesis. Therefore, plasma levels of soluble C-type lectin-like receptor 2 (sCLEC-2), a new marker for platelet activation, can be expected as a marker of DIC in critically ill patients. Plasma levels of sCLEC-2 and D-dimer were measured using the STACIA system. Plasma sCLEC-2 and D-dimer levels were significantly higher in patients with underlying diseases of DIC than in those with unidentified clinical syndrome (UCS). Plasma sCLEC-2 levels were significantly higher in the patients with DIC and Pre-DIC than in those without DIC or Pre-DIC. Similarly, plasma D-dimer levels were also significantly higher in patients with DIC and Pre-DIC than in those without DIC or Pre-DIC. The plasma sCLEC-2 levels in all patients and those with a DIC score ≤ 4 were significantly higher in non-survivors than survivors. The plasma D-dimer levels in all patients, those with a DIC score ≥ 5 and those with a DIC score ≤ 4, were significantly higher in non-survivors than in survivors. The plasma sCLEC-2 is expected as a marker for DIC/Pre-DIC as well as the prognostic marker in critically ill patients.
Identifiants
pubmed: 34203210
pii: jcm10132860
doi: 10.3390/jcm10132860
pmc: PMC8269023
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Hematol. 2019 Sep;110(3):285-294
pubmed: 31165998
Int J Hematol. 2014 Nov;100(5):450-6
pubmed: 25253166
Thromb Haemost. 2001 Nov;86(5):1327-30
pubmed: 11816725
Bibl Haematol. 1983;(49):265-75
pubmed: 6667250
Thromb J. 2018 Jul 11;16:14
pubmed: 30008620
Semin Thromb Hemost. 2014 Nov;40(8):866-73
pubmed: 25377323
J Thromb Haemost. 2020 Jul;18(7):1791-1792
pubmed: 32619344
Semin Thromb Hemost. 2020 Feb;46(1):89-95
pubmed: 31443111
Thromb Res. 2019 Jun;178:54-58
pubmed: 30978634
J Clin Med. 2019 May 22;8(5):
pubmed: 31121897
Clin Chim Acta. 2014 Sep 25;436:130-4
pubmed: 24792730
Thromb Res. 2014 Mar;133(3):440-4
pubmed: 24325877
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620973084
pubmed: 33347372
J Thromb Haemost. 2013 Feb 4;:
pubmed: 23379279
Blood. 2006 Jan 15;107(2):542-9
pubmed: 16174766
Semin Thromb Hemost. 2019 Jun;45(4):342-347
pubmed: 31041800
Clin Appl Thromb Hemost. 2018 May;24(4):655-662
pubmed: 28480752
Blood. 2011 Apr 7;117(14):3912-20
pubmed: 21252089
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620941112
pubmed: 32833540
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936776
pubmed: 32687449
Front Med. 2020 Feb;14(1):81-90
pubmed: 31280468